Literature DB >> 18672599

Botulinum toxin A in surgically overcorrected and undercorrected strabismus.

Sorot Wutthiphan1.   

Abstract

OBJECTIVE: To evaluate the effectiveness and safety of botulinum toxin A injection in treating overcorrected and undercorrected strabismus after unsatisfactory postoperative alignment. MATERIAL AND
METHOD: The authors reviewed the outcomes of 20 patients aged 5 to 56 years (mean 29.1 years) who had botulinum toxin A injection following their unsatisfactory operation. The motor outcomes (percentage of successful motor outcome and percentage change in deviation) were recorded at 1 month, 3 months, 6 months, I year 2 years, 3 years, and 4 years after botulinum toxin injection.
RESULTS: The mean pre-botulinum toxin injection angle of deviation was 20.6 prism dioptors (PD). Six of 20 (30%) patients maintained the successful position for the average of 2.66 years (range 1-4 years) with single injection. The mean percentage change of the deviation was 87.50%, 87.93 %, 73.05 % at 1, 2, and 3-year visit respectively. In 3 of 5 (60%) patients of consecutive esotropia, 4 of 8 (50%) residual esotropia, 1 of 4 (25%) of consecutive exotropia and 1 of 3 (33.33%) of residual exotropia had successful motor alignment at 6 month visit. There was no scleral perforation, visual loss, or retrobulbar hemorrhage from the injection treatment in the present study.
CONCLUSION: Botulinum toxin A injection appears to be a safe and effective treatment for overcorrected and undercorrected strabismus after unsatisfactory surgery. It is very effective in rapid elimination postoperative diplopia. When the result is not adequate or the effect does not last long, repeat the injection or reoperation can be chose to perform later.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18672599

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  1 in total

1.  Botulinum toxin injection without electromyographic guidance in consecutive esotropia.

Authors:  Hee Kyung Yang; Dong Hyun Kim; Jeong-Min Hwang
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.